Project Grant HDTRA11310049

This federal Project Grant award of $949,062 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel nanomaterial-based drug delivery system to improve treatment of Alzheimer's disease (AD) and other dementias. The primary objective is to demonstrate the in vitro and in vivo effectiveness of a natural peptide-based nanostructure called SMC-101 nanotubes (NTs) for transcytosis across the blood-brain barrier and safe delivery of CNS drugs. Key research...

This Cooperative Agreement awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) provides funding to develop novel lipid nanoparticles (LNPs) for the delivery of nucleic acid-based therapeutics to the brain. The $843,806 award, effective from April 10, 2025 to March 31, 2030, supports the Icahn School of Medicine at Mount Sinai (ISMMS) in...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...

This Project Grant award for $506,451 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) aims to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, including Alzheimer's disease. The project leverages the awardee's 3P Biotechnologies, Inc.'s expertise in exosome engineering, drug delivery, and siRNA therapeutics. The key products or services to be delivered under this award...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $2,683,965.00 to Brigham & Women's Hospital Inc. to develop and optimize an improved "all-human" cellular system for studying Alzheimer's disease (AD) and age-related dementias (ADRDS). The key objectives of this 3-year project, which began on May 1, 2025, are...

This Project Grant award of $1,000,000 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to develop novel nanoparticles for the precision delivery of CD33-targeting siRNA to the brain for the treatment of Alzheimer's disease. The key objectives are to characterize the nanoparticles, evaluate their uptake in mouse brain, and assess the therapeutic efficacy of the CD33 siRNA-loaded nanoparticles on CD33 mRNA levels,...

This Project Grant award of $295,000 from the National Institute on Aging (CFDA 93.866 Aging Research program) aims to develop biotherapeutic nanogels for the treatment of Alzheimer's disease (AD). The project will focus on improving the nanogels for enhanced blood-brain barrier transmigration and evaluating their efficacy in a mouse model of AD. Specifically, the nanogels are designed to target key AD biomarkers like amyloid-beta, tau, and neuroinflammation to ameliorate oxidative stress and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $857,315 to Creosalus Inc. to conduct a first-in-human clinical study evaluating the safety and efficacy of the company's Porous Brain Infusion Catheter (PBIC) system for convection-enhanced delivery of therapeutics to recurrent Grade 3-4 glioma patients. The primary objective is to assess the PBIC's safety profile and its ability to achieve significantly greater coverage of enhancing...

This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $758,744 to The University of Kentucky Research Foundation to conduct research aimed at understanding the mechanisms of blood-brain barrier dysfunction in Alzheimer's disease and developing therapeutic strategies to repair this dysfunction. The key objectives of the research are to: 1) Identify the signaling mechanisms by which the protein tau induces blood-brain barrier...

This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...